National Organization for Rare Disorders (NORD). Alport Syndrome. Published 2020. Accessed February 2, 2021. https://rarediseases.org/rare-diseases/alport-syndrome/

• PubMed
National Organization for Rare Disorders (NORD). Alport Syndrome. Published 2020. Accessed February 2, 2021. https://rarediseases.org/rare-diseases/alport-syndrome/ )| false
• Search Google Scholar
• Export Citation

Gross O , et al.. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020; 97:1275−1286. doi: 10.1016/j.kint.2019.12.015

• PubMed
Gross O , . A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020; 97:1275−1286. doi: 10.1016/j.kint.2019.12.015 )| false
• Search Google Scholar
• Export Citation

Kashtan CE , Gross O . Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults—an update for 2020. Pediatr Nephrol 2021; 36:711−719. doi: 10.1007/s00467-020-04819-6.

• PubMed
Kashtan CE , Gross O . Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults—an update for 2020. Pediatr Nephrol 2021; 36:711−719. doi: 10.1007/s00467-020-04819-6.)| false
• Search Google Scholar
• Export Citation

Reata Pharmaceuticals. Reata Announces Positive Results from Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome. November 9, 2020. https://www.reatapharma.com/wp-content/uploads/2020/11/20201109_RETA_PR_CARDINAL_year_2.pdf

• PubMed
Reata Pharmaceuticals. Reata Announces Positive Results from Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome. November 9, 2020. https://www.reatapharma.com/wp-content/uploads/2020/11/20201109_RETA_PR_CARDINAL_year_2.pdf )| false
• Search Google Scholar
• Export Citation

Chen W , et al.. Establishment of microRNA, transcript and protein regulatory networks in Alport syndrome induced pluripotent stem cells. Mol Med Rep 2019; 19:238−250. doi: 10.3892/mmr.2018.9672

• PubMed
Chen W , . Establishment of microRNA, transcript and protein regulatory networks in Alport syndrome induced pluripotent stem cells. Mol Med Rep 2019; 19:238−250. doi: 10.3892/mmr.2018.9672 )| false
• Search Google Scholar
• Export Citation

Chung AC , et al.. MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 2013; 6:169−179. doi: 10.2147/IJNRD.S37885

• PubMed
Chung AC , . MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 2013; 6:169−179. doi: 10.2147/IJNRD.S37885 )| false
• Search Google Scholar
• Export Citation

Study of Lademirsen (SAR339375) in Patients with Alport Syndrome (HERA). ClinicalTrials.gov: NCT02855268. Accessed February 2, 2021. https://clinicaltrials.gov/ct2/show/NCT02855268?cond=alport syndrome&draw=1&rank=3

• PubMed
Study of Lademirsen (SAR339375) in Patients with Alport Syndrome (HERA). ClinicalTrials.gov: NCT02855268. Accessed February 2, 2021. https://clinicaltrials.gov/ct2/show/NCT02855268?cond=alport syndrome&draw=1&rank=3 )| false
• Search Google Scholar
• Export Citation

Atrasentan in Patients with Proteinuric Glomerular Diseases (AFFINITY). ClinicalTrials.gov: NCT04573920. Accessed February 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04573920?cond=alport&draw=3&rank=17

• PubMed
Atrasentan in Patients with Proteinuric Glomerular Diseases (AFFINITY). ClinicalTrials.gov: NCT04573920. Accessed February 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04573920?cond=alport&draw=3&rank=17 )| false
• Search Google Scholar
• Export Citation

Weinstock BA , et al.. Clinical trial recommendations for potential Alport syndrome therapies. Kidney Int 2020; 97:1109−1116. doi: 10.1016/j.kint.2020.02.029

• PubMed
Weinstock BA , . Clinical trial recommendations for potential Alport syndrome therapies. Kidney Int 2020; 97:1109−1116. doi: 10.1016/j.kint.2020.02.029 )| false
• Search Google Scholar
• Export Citation